Cargando…

Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey

BACKGROUND: The financial burden of medical expenses has been increasing for cancer patients. We investigated the relationship between household income and financial burden among patients with chronic myelogenous leukaemia (CML) who have been treated with imatinib. METHODS: A questionnaire was distr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kodama, Yuko, Morozumi, Ryoko, Matsumura, Tomoko, Kishi, Yukiko, Murashige, Naoko, Tanaka, Yuji, Takita, Morihito, Hatanaka, Nobuyo, Kusumi, Eiji, Kami, Masahiro, Matsui, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502305/ https://www.ncbi.nlm.nih.gov/pubmed/22530992 http://dx.doi.org/10.1186/1471-2407-12-152

Ejemplares similares

Data mining of mental health issues of non-bone marrow donor siblings
por: Takita, Morihito, et al.
Publicado: (2011)

A study of the changes in how medically related events are reported in Japanese newspapers
por: Kishi, Yukiko, et al.
Publicado: (2010)

Myelogenic Leukaemia
Publicado: (1915)

Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing
por: Takita, Morihito, et al.
Publicado: (2020)

Forecasting Japan's Physician Shortage in 2035 as the First Full-Fledged Aged Society
por: Yuji, Koichiro, et al.
Publicado: (2012)

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
por: Topaly, J, et al.
Publicado: (2002)

Immunotherapy for Acute Myelogenous Leukaemia
por: Powles, R. L., et al.
Publicado: (1973)

Myelogenous Leukæmia and Its Treatment
por: Debove,
Publicado: (1910)

ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
por: Perrotti, D, et al.
Publicado: (2006)

The Proportion of Female Physician Links With Advanced Educational Opportunity for Female and by Female
por: Senoo, Yuki, et al.
Publicado: (2020)

A Case of Exacerbation of Subclinical Hyperthyroidism after First Administration of BNT162b2 mRNA COVID-19 Vaccine
por: Yamamoto, Kana, et al.
Publicado: (2021)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia
por: Von Laffert, Maximilian, et al.
Publicado: (2016)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

Japan's COVID-19 response: underutilized beds and misused funds
por: Saito, Yoshika, et al.
Publicado: (2023)

Factors influencing prognosis in adults with acute myelogenous leukaemia.
por: Crowther, D., et al.
Publicado: (1975)

Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia.
por: Cocks, P., et al.
Publicado: (1977)

Time-Dependent Changes in Death Reports and the Sex Ratio in the Safety Surveillance of SARS-CoV-2 Vaccination in Japan, the United States, and European Countries
por: Yamashita, Erika, et al.
Publicado: (2022)

Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
por: Zuhrie, S. R., et al.
Publicado: (1980)

Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
por: Smith, B. J., et al.
Publicado: (1976)

A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia
por: Hu, C. W., et al.
Publicado: (2019)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

How do medical journalists treat cancer-related issues?
por: Nakada, Haruka, et al.
Publicado: (2015)

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
por: Cowan-Jacob, Sandra W., et al.
Publicado: (2006)

Cytogenetic analysis of leukaemic colonies from acute and chronic myelogenous leukaemia.
por: Trent, J. M., et al.
Publicado: (1983)

Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
por: Harris, R., et al.
Publicado: (1978)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Changes in the cause of death in Japan before and during the COVID-19 pandemic
por: Uchi, Yuna, et al.
Publicado: (2023)

In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
por: Marie, J. P., et al.
Publicado: (1988)

Sensitivity of normal and acute myelogenous leukaemia marrow cells to inhibition by cytosine arabinoside.
por: Potter, C. G., et al.
Publicado: (1980)

Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia
por: Dalley, C D, et al.
Publicado: (2001)

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia
por: Lee, C-Y, et al.
Publicado: (2007)

Early central nervous system involvement in adults with acute non-myelogenous leukaemia.
por: Lister, T. A., et al.
Publicado: (1977)

Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India
por: Anand, Maninder Singh, et al.
Publicado: (2012)

OGG1 rs1052133 Polymorphism and Genetic Susceptibility to Chronic Myelogenous Leukaemia
por: Hassan, Fathelrahman M
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ul1do2c4k32ku92hc9dig5l97r